Novo Nordisk’s next-generation weight-loss drug CagriSema
5 天之前 · The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people ...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
5 天之前 · The data from Novo's CagriSema Phase III trial was based on about 3,400 people with a body mass index (BMI) of 30 or above or people with a BMI of 27 and at least one weight-related comorbidity ...
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in …
2 天之前 · CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. ... Following the news, shares of Novo Nordisk’s archrival in the obesity market space ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
5 天之前 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
5 天之前 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Novo’s next-gen obesity drug misses expectations in closely …
6 天之前 · The trial results announced Friday are a blow to Novo’s o besity ambitions, then, disappointing analysts and investors eager for signs it can continue to dominate a drug class projected to eventually surpass $100 billion in yearly sales. David Risinger, an analyst with Leerink Partners, wrote that, in light of the findings, “it …
Drugmakers are racing to find the next Wegovy. These obesity …
2024年10月10日 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.
Novo’s CagriSema Obesity Shot Shortfall Shows Danger of …
5 天之前 · Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs.
Novo Nordisk to explore CagriSema weight-loss potential in new …
5 天之前 · Earlier on Friday, Novo said CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.
Novo Nordisk's CagriSema Shows Superior, But Lower-than …
5 天之前 · After 68 weeks, 57.3 percent of patients treated with CagriSema were on the highest dose, compared to 82.5 percent with cagrilintide 2.4 mg and 70.2 percent with semaglutide 2.4 mg.